다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of hepatology : the journal of the European Association for the Study of the Liver, v.28 no.3, 1998년, pp.375 - 381
Leroy, V. (aDepartement d'Hepato-gastroenterologie, CHU ,, Grenoble, France) , Baud, M. , de Traversay, C. , Maynard-Muet, M. , Lebon, P. , Zarski, J.-P.
AI-Helper
Background/Aims: Alpha interferon induces aminotransferase normalization in about 50% of patients with chronic viral hepatitis C. However, some patients who initially respond experience a relapse during the treatment period (breakthrough phenomenon). The aim of this study was to evaluate the prevale...
Gastroenterology Causse 101 497 1991 10.1016/0016-5085(91)90030-O Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis
N Engl J Med Davis 321 1501 1989 10.1056/NEJM198911303212203 Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
Hepatology Marcellin 13 393 1991 10.1002/hep.1840130302 Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France
J Hepatol Saracco 11 43 1990 10.1016/0168-8278(90)90162-K A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis
Hepatology Shindo 15 1013 1992 10.1002/hep.1840150607 Long term follow-up of patients with chronic hepatitis C treated with alpha interferon
Hepatology Poynard 24 778 1996 10.1002/hep.510240405 Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration
Hepatology Roffi 21 645 1995 10.1002/hep.1840210307 Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology and management
Am J Gastroenterol Lebovics 90 951 1995 The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome
J Hepatol Bellati 26 449 1997 10.1016/S0168-8278(97)80069-4 Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon
Br J Haematol Hanley 94 551 1996 10.1046/j.1365-2141.1996.6772294.x Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in hemophiliacs
Hepatology Pawlotsky 22 114 1995 Breakthrough during interferon therapy for chronic hepatitis C: evolution of HCV replication and evaluation of predictive factors [abstract]
J Clin Microbiol Lebon 21 775 1985 10.1128/JCM.21.5.775-778.1985 Presence of an acid-labile alpha interferon in sera from fetuses and children with congenital rubella
Hepatology Knodell 1 431 1981 10.1002/hep.1840010511 Formulation and application of a numerical scoring system for assessing histoligical activity in asymptomatic chronic active hepatitis
Nature Vallbracht 289 496 1981 10.1038/289496a0 Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon
J Infect Dis Antonelli 163 882 1991 10.1093/infdis/163.4.882 Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparations
Am J Med Spiegel 80 223 1986 10.1016/0002-9343(86)90013-6 Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (intron A)
J Interferon Res Finter 185 1991 Why are there so many subtypes of alpha-interferons?
Hepatology Carreno 22 176 1995 10.1016/0270-9139(95)94427-3 Genotype dependant response to interferon alpha-2a in patients with chronic hepatitis C [abstract]
N Engl J Med Steis 318 1409 1988 10.1056/NEJM198806023182201 Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies
J Hepatol Porres 8 351 1989 10.1016/0168-8278(89)90034-2 Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon
Hepatology Suk-Fong Lok 12 1266 1990 10.1002/hep.1840120603 Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection
Liver Milella 13 146 1993 10.1111/j.1600-0676.1993.tb00622.x Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection
J Hepatol Bonetti 20 416 1994 10.1016/S0168-8278(94)80018-9 Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2a
Cancer Itri 59 668 1987 10.1002/1097-0142(19870201)59:3+<668::AID-CNCR2820591317>3.0.CO;2-J Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant alfa-2a by intramuscular injection
J Interferon Res Weck 9 37 1989 Detection and incidence of neutralizing antibodies to interferon alpha n1
Hepatology Rumi 24 1366 1996 10.1002/hep.510240609 A prospective randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C
Blood Billard 67 821 1986 10.1182/blood.V67.3.821.821 Treatment of hairy cell leukemia with recombinant alpha interferon: in vivo down-regulation of alpha interferon receptors on tumor cells
Hepatology Nakajima 12 1261 1990 10.1002/hep.1840120602 Changes in interferon receptors on peripheral blood mononuclear cell from patients with chronic hepatitis B being treated with interferon
Hepatology Okada 16 619 1992 10.1002/hep.1840160302 The degree of variability in the amino terminal of the E2/NS1 protien of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
Hepatology Koizumi 22 30 1995 Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment
Gastroenterology Moribe 108 789 1995 10.1016/0016-5085(95)90452-2 Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy
J Med Virol Gonzalez-Peralta 49 242 1996 10.1002/(SICI)1096-9071(199607)49:3<242::AID-JMV14>3.0.CO;2-E Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C
Arch Virol Sakuma 141 1921 1996 10.1007/BF01718204 Seletion of hepatitis C virus quasispecies during interferon treatment
Hepatology Shindo 24 1018 1996 10.1002/hep.510240507 The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.